Novartis bags FDA priority review in tight lung cancer race against Merck KGaA

11th February 2020 Uncategorised 0

At last year’s American Society of Clinical Oncology meeting, both Novartis and Merck KGaA rolled out data for their drugs aimed at MET exon 14 skipping-mutated non-small cell lung cancer. Now thanks to an FDA priority review for capmatinib, Novartis is one step ahead.

More: Novartis bags FDA priority review in tight lung cancer race against Merck KGaA
Source: fierce